Effect of soy lecithin on fatigue and menopausal symptoms in middle-aged women: a randomized, double-blind, placebo-controlled study

Asuka Hirose¹², Masakazu Terauchi²*, Yurika Osaka¹, Mihoko Akiyoshi¹, Kiyoko Kato² and Naoyuki Miyasaka¹

Abstract

Background: Lecithin is a complex mixture of phospholipids which compose lipid bilayer cell membranes. Lipid replacement therapy, or administration of phospholipids for the purpose of repairing the damaged cell membranes, had been shown to alleviate fatigue. The present study aimed to investigate the effect of soy lecithin on fatigue in middle-aged women, as well as other menopausal symptoms and various health parameters.

Methods: This randomized, double-blind, placebo-controlled study included 96 women aged 40 to 60 years who complained of fatigue. The participants were randomized to receive active tablets containing high-dose (1200 mg/day; n = 32) or low-dose (600 mg/day; n = 32) soy lecithin, or placebo (n = 32), for 8 weeks. The following parameters were evaluated: age, menopausal status, lifestyle factors, physical and psychological symptoms of menopause, subjective symptoms of insomnia and fatigue, body composition, cardiovascular parameters, and physical activities and objective sleep states obtained from actigraphy before and 4 and 8 weeks after treatment. Fatigue was evaluated using the Profile of Mood States (POMS)-brief, Menopausal Health-Related Quality of Life questionnaire, Chalder Fatigue Scale, and Brief Fatigue Inventory.

Results: Eighty-nine women completed the study. There were no significant differences in the changes in Chalder Fatigue Scale score (placebo vs low-dose vs high-dose groups: −2.9 ± 1.1, −3.2 ± 1.1, and −3.5 ± 1.0; P = 0.79). On the other hand, the improvements were greater in the high-dose group compared with the placebo group concerning vigor scores in the POMS-brief (1.9 ± 0.7 vs 0.2 ± 0.6; P = 0.02), diastolic blood pressure (−4.1 ± 1.8 vs 1.2 ± 1.9; P = 0.05), and cardio-ankle vascular index (−0.4 ± 0.2 vs 0.07 ± 0.1; P = 0.03) after 8 weeks of treatment.

Conclusions: High-dose (1200 mg/day) soy lecithin not only increases vigor, but also lowers the diastolic blood pressure and cardio-ankle vascular index in middle-aged women who present with fatigue.

Trial registration: UMIN-CTR UMIN000017127.

Keywords: Atherosclerosis, Cardiovascular risks, Fatigue, Lipid replacement therapy, Menopausal symptoms, Psychological symptoms, Soy

* Correspondence: teragyne@tmd.ac.jp
²Department of Women's Health, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo, Tokyo 113-8510, Japan

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Middle-aged women are bothered by various symptoms such as hot flashes, night sweats, anxiety, depression, insomnia, and fatigue. A previous study revealed that 86% of Japanese middle-aged women who visited our menopausal clinic felt tiredness more than once a week, and 49% felt it almost every day [1]. Another study revealed that 85% of Japanese and 82% of Australian middle-aged women felt fatigue, at least to some extent [2]. Compared to the patients attending a primary care clinic of whom 14% complained of fatigue [3], apparently more middle-aged women are bothered by the symptom.

Lecithin is a complex mixture of phospholipids found mainly in egg yolks, soy, and coleseeds. Phospholipids such as phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, and phosphatidyl glycerol compose the lipid bilayer of the cellular membrane structure. Membrane lipids are used for energy storage necessary for membrane biogenesis [4–6]. The matrix of cellular membranes is formed by polar lipids, which consist of a hydrophobic and hydrophilic portion and segregate the internal and external environment [6]. Furthermore, membrane lipids act as first and second messengers in signal transduction and molecular recognition pathways [4, 6], implying the variability of their biological roles. The administration of fresh phospholipids to replace damaged cell membranes and restore the structure and function of the cellular membrane is called lipid replacement therapy (LRT). LRT has been shown to improve fatigue, and is expected to be effective for the treatment of degenerative diseases, metabolic syndrome, diabetes, and cardiovascular diseases [4, 7]. However, previous studies have demonstrated the effects of LRT using a supplement containing not only phospholipids but also other active ingredients. To the best of our knowledge, this study is the first to examine the effects of soy lecithin on fatigue.

The present study aimed to investigate the effect of soy lecithin on menopausal symptoms including fatigue and other various health parameters in Japanese middle-aged women.

Methods
Study population
We performed a randomized, double-blind, placebo-controlled study from February to July 2015 at the Menopause Clinic of Tokyo Medical and Dental University. The study protocol was reviewed and approved by the Tokyo Medical and Dental University Review Board, and written informed consent was obtained from all the participants. The present study was conducted in accordance with the Declaration of Helsinki.

Ninety-six Japanese women aged 40 to 59 years who complained of fatigue participated in this study. Fatigue was evaluated using the item about fatigue in the Menopausal Health-Related Quality of Life (MHR-QOL) questionnaire. The participants were recruited through advertisements posted in our hospital and in the patients’ social network. Those who were receiving menopausal hormone therapy, herbal medicine, or psychotropic drugs were excluded. Collected data included age, menopausal status, lifestyle factors, physical and psychological symptoms of menopause, subjective symptoms of insomnia and fatigue, body composition, cardiovascular parameters, and physical activities and objective sleep states obtained from actigraphy. The data were evaluated before and 4 and 8 weeks after treatment. Regarding menopausal status, participants were classified as follows: premenopausal (regular menstrual cycles in the past 3 months), perimenopausal (a menstrual period within the past 12 months but a missed period or irregular cycles in the past 3 months), postmenopausal (no menstrual period in the past 12 months), or surgically induced menopause (hysterectomy).

Randomization and intervention
The participants were randomized into 1 of 3 groups to receive active tablets containing high-dose (1200 mg/day; n = 32) or low-dose (600 mg/day; n = 32) soy lecithin, or placebo (n = 32) for 8 weeks. The high-dose and low-dose soy lecithin and placebo tablets, indistinguishable in shape, weight, and color, were manufactured and packaged by Kikkoman Corporation (Noda, Japan). The tablet contained phospholipids in the form of phosphatidylycholine, 24%; phosphatidylethanolamine, 20%; and phosphatidylinositol, 12%. The women were instructed to take six tablets per day after breakfast. Medication adherence was evaluated by collecting the packages of the supplements from participants. The participants were sequentially numbered, and received supplement packages with the corresponding number. The content of each package, namely high-dose or low-dose soy lecithin, or placebo, was known only by the manufacturers. Thus, allocation was concealed from both the participants and the investigators. Safety was assessed by patient-reported treatment-emergent adverse events.

Menopausal symptoms
Menopausal symptoms were evaluated using the Menopausal Health-Related Quality of Life (MHR-QOL) questionnaire, Hospital Anxiety and Depression Scale (HADS), and Athens Insomnia Scale (AIS). The MHR-QOL questionnaire, developed and validated at our clinic [8, 9], is a modification of the Women’s Health Questionnaire [10, 11], and contains 38 items scored on a 4-point or binary scale covering four major domains (physical symptoms, psychological symptoms, life satisfaction, and social involvement) of a woman’s health during menopause. The
HADS [12] is a reliable instrument for screening clinically significant anxiety and depression in women visiting a general medicine clinic. The translated Japanese version of the HADS [13] was used in the present study. The AIS was developed as a brief and easy-to-administer self-assessment questionnaire for determining the severity of insomnia defined according to the International Classification of Diseases 10th Revision. The internal consistency and test-retest reliability of the AIS have been confirmed previously [14]. Detailed information about the MHR-QOL questionnaire, HADS, and AIS is provided elsewhere [8].

Fatigue and mood states
Fatigue and mood states were evaluated by the Profile of Mood States (POMS)-brief, Chalder Fatigue Scale (CFS), and Brief Fatigue Inventory (BFI). The POMS is a psychological rating scale used to assess feelings and mood states. The original version of the POMS consists of 65 items, while the POMS-brief, a shortened version, includes 30 items covering six major domains (tension, depression, anger, vigor, fatigue, and confusion). Because the latter is easier to complete and its validity has been demonstrated [15], it is now more widely used than the original form. The POMS-brief was translated into Japanese, and its reliability and validity were confirmed previously [16]. The CFS is a self-administered questionnaire with 14 items which evaluates fatigue-related symptoms by using a 4-point Likert scale for the extent or frequency of the symptoms [17]. Although originally developed to measure fatigue symptoms in clinical settings, the scale is now more widely used [18]. The BFI, a self-rating assessment composed of 9 items using a numerical scale of 0 to 10, was developed for the rapid assessment of fatigue severity in cancer patients [19]. It was translated into Japanese, and its reliability and validity were confirmed previously [20].

Body composition and cardiovascular parameters
Height, weight, body mass index, and body composition including fat mass, and fat free mass, was assessed using a body composition analyzer (MC190-EM; Tanita, Tokyo, Japan). Cardiovascular parameters, including systolic and diastolic blood pressure, heart rate, and the cardio-ankle vascular index (CAVI), were measured using a vascular screening system (VS-1000; Fukuda Denshi Co., Tokyo, Japan).

Physical activities and objective sleep states
We investigated physical activities and objective sleep states using the actigraphy system that is loaded with a miniature triaxial acceleration sensor (Wrist-worn Accelerometers; Hitachi Ltd., Tokyo, Japan). It measured motion with accelerometers and sleep–wake identification was automatically performed by using the Cole–Kripke algorithm. The outcome measures included zero-crossing (ZC) and metabolic equivalents (METs) during the awake and sleep phase, total sleep time, day-to-day variation of sleep time, episodes of nocturnal awakening, sleep latency, and sleep efficiency. ZC is the rate of signal changes from the triaxial acceleration sensor, representing the frequency of wrist motion. METs are calculated as the ratio of metabolic rate relative to that in resting, representing the intensity of exercise. We define sleep latency as the time from time in bed to the start of identification of sleep. Sleep efficiency is calculated as pure sleep time (time in bed minus awake time) divided by time in bed.

Statistical analyses
The baseline characteristics of the participants who completed the 8-week treatment were compared using one-way analysis of variance, χ² test, and Kruskal-Wallis test. Then, the changes from baseline to 8 weeks of treatment in all of the collected data were evaluated using Mann-Whitney test and unpaired t-test. All statistical analyses were performed with GraphPad Prism version 5.02 (GraphPad Software Incorporated, CA, USA). A P-value <0.05 was considered statistically significant.

Results
A total of 96 middle-aged women were enrolled in the study and were randomized to the high-dose (n = 32), low-dose (n = 32), or placebo groups (n = 32); of these, 89 (94%) completed the 8-week treatment period (Fig. 1). During the study period, seven women dropped out of the study. Five of them did not continue to take the supplements, and two did not have an examination at our clinic. The baseline characteristics of the participants who completed the 8-week treatment are shown in Table 1. The group mean age ranged from 49 to 51 years. The proportion of women who were premenopausal, perimenopausal, postmenopausal, and had surgically induced menopause ranged from 22 to 52%, 7 to 22%, 41 to 53%, and 0 to 7%, respectively. The weight, body mass index, and body fat mass were significantly higher in the high-dose group than the other groups (P = 0.018, 0.012, and 0.008, respectively).

The mean ± SEM CFS scores significantly decreased after 8 weeks of treatment in all the groups, and there were no significant differences among the groups (placebo vs low-dose vs high-dose groups: −2.9 ± 1.1, −3.2 ± 1.1, and −3.5 ± 1.0, respectively; P = 0.79, Kruskal-Wallis test, Fig. 2a). After 8 weeks of treatment, the mean ± SEM POMS-vigor score was significantly higher in the high-
dose group than the placebo group (1.9 ± 0.7 vs 0.2 ± 0.6, respectively; \(P = 0.02\), Mann-Whitney test, Fig. 2b). The mean ± SEM diastolic blood pressure (−4.1 ± 1.8 vs 1.2 ± 1.9; \(P = 0.05\), unpaired t-test, Fig. 2c) and CAVI (−0.4 ± 0.2 vs 0.07 ± 0.1; \(P = 0.03\), unpaired t-test, Fig. 2d) significantly decreased after 8 weeks of treatment in the high-dose group compared with the placebo group. Neither the body composition parameters nor the actigraphic parameters changed significantly in any of the groups (data not shown).

During the whole study period, no treatment-emergent adverse event was reported by the participants, even though laboratory tests were not routinely performed.

**Discussion**

In this randomized, double-blind, placebo-controlled study, the effect of soy lecithin on menopausal symptoms including fatigue and other various health parameters in Japanese middle-aged women was investigated. The results showed that high-dose (1200 mg/day) soy lecithin not only increases vigor, but also lowers the diastolic blood pressure and CAVI in Japanese middle-aged women who complained of fatigue.

Lecithin is particularly abundant in egg yolks, soybeans, organ and lean meats, and fish. The total phospholipids contained in 100 g of egg yolk and soybeans are 31.8 g and 20.8 g, respectively [25], and the normal dietary intake of phospholipids is estimated as 2–8 g per day [26]. Most previous studies [4, 7, 26] have used the dosage of 1 to 3 g per day of oral supplementation of lecithin, exhibiting its effects for inflammatory diseases, hyperlipidemia, cardiovascular diseases, cognitive impairment, and fatiguing illnesses. Oral administration of phospholipids has been shown to be generally safe [4]. For example, in phase I and II clinical trials in patients with cardiovascular diseases, over 5 g of soy phospholipids were administered with no apparent toxicity [27]. Referring to older studies, a daily dosage of as much as 54 g has been administered without any apparent adverse effects [28]. Regarding the duration of the treatment, most of the previous studies investigating the effects of dietary LRT supplement on fatigue examined for 8 weeks, meanwhile some examined for 1 or 12 weeks [4].

In this study, the effect of soy lecithin on fatigue and other factors was investigated, and our findings showed that lecithin promotes vigor assessed by the POMS-brief questionnaire. Previous studies have demonstrated the effect of phospholipids on cancer-associated fatigue and adverse chemotherapy effects, such as nausea, diarrhea, constipation, and fatigue [29, 30], using NT Factor® (Nutritional Therapeutics, Inc., Hauppauge, NY.), an oral supplement containing phospholipids, glycolipids, and other membrane lipids [23]. Feelings of fatigue and loss of vigor are similar and the difference is ambiguous, and our result can be understood in the same context. In this study, significant differences in the fatigue scores among the groups could not be shown. The reason for this may be the placebo effect because the fatigue scores were improved in all groups, and it was explained to the participants that lecithin might improve fatigue. Other reasons why the improvement of fatigue was not different among the groups might be

![Study participants](image.png)

**Fig. 1 Participant disposition**
|                                | Placebo (n = 32) | Low-dose lecithin (n = 30) | High-dose lecithin (n = 27) | P value |
|--------------------------------|-----------------|---------------------------|-----------------------------|---------|
| **Age, y**                     | 51.2 ± 5.2      | 50.3 ± 5.8                | 49.3 ± 4.8                  | 0.423   |
| **Menopausal status, n (%)**   |                 |                           |                            |         |
| Premenopausal                  | 7 (21.9)        | 10 (33.3)                 | 14 (51.9)                  | 0.222   |
| Perimenopausal                 | 7 (21.9)        | 5 (16.7)                  | 2 (7.4)                    |         |
| Postmenopausal                 | 17 (53.1)       | 13 (43.3)                 | 11 (40.7)                  |         |
| Surgically induced menopause   | 1 (3.1)         | 2 (6.7)                   | 0 (0)                      |         |
| **Questionnaire**              |                 |                           |                            |         |
| MHR-QOL physical symptom score | 21.2 ± 3.5      | 21.9 ± 2.9                | 20.6 ± 3.2                  | 0.406   |
| MHR-QOL psychological symptom score | 27.1 ± 8.0    | 29.7 ± 6.7                | 30.0 ± 5.5                  | 0.328   |
| HADS-anxiety subscale score    | 5.8 ± 2.9       | 5.3 ± 3.3                 | 4.9 ± 2.7                   | 0.549   |
| HADS-depression subscale score | 5.5 ± 3.7       | 4.8 ± 3.7                 | 4.7 ± 3.1                   | 0.679   |
| AIS score                      | 5.0 ± 3.0       | 4.0 ± 2.9                 | 4.1 ± 2.6                   | 0.443   |
| Chalder Fatigue Scale          | 18.7 ± 8.3      | 17.1 ± 5.3                | 17.6 ± 6.6                  | 0.628   |
| Brief Fatigue Inventory        | 27.1 ± 1.9      | 30.0 ± 1.7                | 30.0 ± 2.0                  | 0.575   |
| POMS-tension                   | 6.1 ± 4.9       | 5.5 ± 4.3                 | 4.3 ± 3.1                   | 0.461   |
| POMS-depression                | 3.9 ± 3.9       | 2.5 ± 3.1                 | 2.5 ± 2.6                   | 0.217   |
| POMS-anger                     | 5.1 ± 4.2       | 3.7 ± 3.1                 | 2.8 ± 2.5                   | 0.104   |
| POMS-vigor                     | 7.7 ± 4.1       | 7.2 ± 3.6                 | 6.1 ± 3.5                   | 0.179   |
| POMS-fatigue                   | 6.8 ± 4.4       | 7.8 ± 4.3                 | 6.4 ± 3.6                   | 0.727   |
| POMS-confusion                 | 5.0 ± 2.8       | 4.8 ± 2.4                 | 3.8 ± 2.2                   | 0.323   |
| **Body composition**           |                 |                           |                            |         |
| Height, cm                     | 157.6 ± 4.6     | 158.4 ± 5.1               | 158.0 ± 3.8                 | 0.817   |
| Weight, kg                     | 52.8 ± 7.5      | 52.6 ± 6.0                | 58.3 ± 11.1                 | 0.018   |
| Body mass index, kg/cm²        | 21.2 ± 2.8      | 21.0 ± 2.5                | 23.3 ± 4.0                  | 0.012   |
| Body fat mass, kg              | 14.0 ± 5.1      | 13.7 ± 4.4                | 18.5 ± 8.5                  | 0.008   |
| Fat free mass, kg              | 36.5 ± 2.8      | 36.6 ± 2.2                | 37.6 ± 2.8                  | 0.222   |
| Waist hip ratio, %             | 80.6 ± 6.1      | 81.7 ± 4.8                | 83.4 ± 6.2                  | 0.191   |
| Body temperature, °C           | 36.3 ± 0.33     | 36.4 ± 0.42               | 36.3 ± 0.41                 | 0.701   |
| **Cardiovascular parameters**  |                 |                           |                            |         |
| Systolic blood pressure, mmHg  | 122.7 ± 15.7    | 119.3 ± 16.1              | 119.9 ± 13.6                | 0.668   |
| Diastolic blood pressure, mmHg | 69.2 ± 12.1     | 67.8 ± 13.6               | 68.7 ± 13.6                 | 0.919   |
| Heart rate, beats/min          | 77.2 ± 8.0      | 76.9 ± 12.7               | 80.1 ± 12.4                 | 0.504   |
| Cardio-ankle vascular index    | 7.19 ± 0.79     | 7.24 ± 0.79               | 7.14 ± 0.78                 | 0.967   |
| **Actigraphy**                 |                 |                           |                            |         |
| Active ZC / (min)              | 156.6 ± 26.2    | 148.0 ± 31.8              | 149.0 ± 34.0                | 0.506   |
| Sleep ZC / (min)               | 43.3 ± 1.1      | 43.4 ± 1.8                | 47.3 ± 1.7                  | 0.606   |
| Active METs                    | 1.6 ± 0.15      | 1.5 ± 0.14                | 1.6 ± 0.21                  | 0.674   |
| Sleep METs                     | 1.1 ± 0.015     | 1.1 ± 0.015               | 1.1 ± 0.019                 | 0.580   |
| Sleep time (min/day)           | 372.1 ± 70.6    | 374.4 ± 60.6              | 367.8 ± 54.8                | 0.687   |
| Sleep efficiency (%)           | 97.2 ± 1.4      | 97.4 ± 1.7                | 97.5 ± 1.8                  | 0.719   |
| Episodes of nocturnal awakening (>1 min) / (day) | 1.7 ± 1.2 | 1.8 ± 1.4 | 1.8 ± 1.5 | 0.676 |
| **Lifestyle factors, %**       |                 |                           |                            |         |
| Exercising regularly           | 50.0            | 46.7                      | 51.9                        | 0.923   |
| Smoking                        | 625             | 100                       | 7.4                         | 0.856   |
| Drinking alcohol (daily / by chance / not at all) | 15.6 / 688 / 15.6 | 200 / 633 / 16.7 | 206 / 593 / 11.1 | 0.749   |

Values are presented as mean ± SD unless otherwise indicated

*All Athens Insomnia Scale, CAVI cardio-ankle vascular index, HADS Hospital Anxiety and Depression Scale, METs metabolic equivalents, MHR-QOL Menopausal Health-Related Quality of Life, POMS Profile of Mood States, ZC, zero-crossing

aOne-way analysis of variance

bChi-square test
cKruskal-Wallis test
that the participants were relatively healthy and the baseline fatigue scores were not high enough, or that some portion of the fatigue experienced by the participants was derived from pathological conditions, such as infection, inflammation, and sleep disorders.

The present study also revealed that lecithin decreases the diastolic blood pressure and CAVI. The risk of cardiovascular diseases (CVDs), including central obesity, hypertension, dyslipidemia, and diabetes, increases after menopause [31–34], partly as a result of diminished estrogen production [35]. CVD is rare in young women, but it is the second leading cause of death among the 45–64 year age group in the United States after cancer, and it has become the leading cause after the age of 65 years [36]. Especially in women, the treatment of arterial hypertension and diabetes is considered important for the prevention of CVD [37]. Several studies demonstrated that lecithin lowered total cholesterol in patients with primary hyperlipidemia [38, 39], and a mini-pig study showed that LRT reduced atherosclerotic plaques in the aortas and heart valves [40]. There is a possibility that lecithin lowers cardiovascular risks, although the mechanisms are yet to be elucidated. This is the first study showing the effects of lecithin on the diastolic blood pressure and CAVI. Further study is warranted to corroborate the findings and also to examine the effect on systolic blood pressure. In the present study, there was statistically significant differences in the baseline characteristics among the study groups, that is weight, body mass index, and body fat mass were significantly higher in the high-dose group. On the other hand, there was no significant difference in the POMS-vigor score, diastolic blood pressure, and CAVI that changed significantly after the 8-week treatment, therefore we consider that the differences in the baseline characteristics would have a small influence on the results of the present study.

The present study has some limitations. First, the sample size was relatively small and the study period was as short as 8 weeks, and all the participants were relatively healthy women. Second, mitochondrial function was not evaluated, and the results could not be directly explained by the functional improvement of the mitochondria. Finally, we set the full dose as 1200 mg in this study, which might not be sufficient. Further studies with longer duration enrolling more patients with severe fatigue, hypertension, or established atherosclerosis are warranted in order to corroborate our findings concerning the effects of soy lecithin on vigor and cardiovascular risks. Higher doses of lecithin and simultaneous assessment of the mitochondrial function may be needed to evaluate the effects of the compound.
Conclusions

High-dose (1200 mg/day) soy lecithin not only increases vigor, but also lowers the diastolic blood pressure and CAVI in middle-aged women who present with fatigue. Further studies with longer duration enrolling more patients with severe fatigue are warranted in order to corroborate our findings.

Abbreviations

ASIS: Athens insomnia scale; ATP: Adenosine triphosphate; BFI: Brief fatigue inventory; CAVI: Cardioankle vascular index; CFS: Chalder fatigue scale; CVD: Cardiovascular disease; HADS: Hospital anxiety and depression scale; LRT: Lipid replacement therapy; MET: Metabolic equivalent; MHR-QOL: Menopausal health-related quality of life; POMS: Profile of mood states; ROS: Reactive oxygen species; ZC: Zero-crossing

Acknowledgements

Not applicable.

Funding

MT received an unrestricted research grant from Kikkoman Corporation.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

AH and MT were responsible for project development, data collection, and data analysis. YO, MA, and KK were responsible for data collection. NM participated in the project development and supervision. All authors contributed to reviewing, editing, and approving the final manuscript.

Ethics approval and consent to participate

The study protocol was reviewed and approved by the Tokyo Medical and Dental University Review Board, and written informed consent was obtained from all of the participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Department of Obstetrics and Gynecology, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo, Tokyo 113-8510, Japan. 2. Department of Women’s Health, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo, Tokyo 113-8510, Japan.

Received: 10 August 2017 Accepted: 2 January 2018 Published online: 08 January 2018

References

1. Terauchi M, Hiramitsu S, Akiyoshi M, Owa Y, Kato K, Obayashi S, et al. Effects of the kampo formula toki-shakuyakusan on headaches and concomitant depression in middle-aged women. Evid Based Complement Alternat Med. 2014;2014:595360.
2. Anderson DO, Yoshizawa T, Gollichevski S, Atogami F, Courtney M. Menopause in Australia and Japan: effects of country of residence on menopausal status and menopausal symptoms. Climacteric. 2004;7:165–74.
3. Cathnábris PJ, Robbins JM, Kirmayer LJ, Hayton BC. Fatigue in primary care: prevalence, psychiatric comorbidity, illness behavior, and outcome. J Gen Intern Med. 1992;7:176–86.
4. Nicolson GL, Ash ME. Lipid replacement therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring function. Biochim Biophys Acta. 1838(2014):1657–79.
5. Shevchenko A, Simons K. Lipidomics: coming to grips with lipid diversity. Nat Rev Mol Cell Biol. 2010;11:593–8.
6. van Meeg D, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9:112–24.
7. Küllenberg D, Taylor LA, Schneider M, Massing U. Health effects of dietary phospholipids. Lipids Health Dis. 2012;11:3.
8. Terauchi M, Horiguchi N, Kajiyama A, Akiyoshi M, Owa Y, Kato K, et al. Effects of grape seed proanthocyanidin extract on menopausal symptoms, body composition, and cardiovascular parameters in middle-aged women: a randomized, double-blind, placebo-controlled pilot study. Menopause. 2014;21:990–6.
9. Terauchi M, Obayashi S, Akiyoshi M, Kato K, Matsushima E, Kubota T. Insomnia in Japanese peri- and postmenopausal women. Climacteric. 2010;13:479–86.
10. Hunter M, Battersby R, Whitehead M. Relationships between psychological symptoms, somatic complaints and menopausal status. Maturitas. 1986;8:217–28.
11. Hunter M. The south-east England longitudinal study of the climacteric and postmenopause. Maturitas. 1992;14:117–26.
12. Zigmond AS, Snith RP. The hospital anxiety and depression scale. Acta Psychiatri Scand. 1983;67:361–70.
13. Zigmond AS, Snith RP, Kitamura T. The hospital anxiety and depression scale (in Japanese). Seisinka-Sindangaku. 1993;4:371–2.
14. Solidatos CR, Dikeos DG, Paparrigopoulos TJ. Athens insomnia scale validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48:555–60.
15. Yeun EI, Shin-Park KK. Verification of the profile of mood states-brief: cross-cultural analysis. J Clin Psychol. 2006;62:1173–80.
16. Yokoyama K, Araki S, Kawakami N, Takahata T. Production of the Japanese edition of profile of mood states (POMS): assessment of reliability and validity. Nihon Koshu Eisei Zasshi. 1990;37:913–8.
17. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37:147–53.
18. Jackson C. The Chalder fatigue scale (CFQ 11). Occup Med (Lond). 2015;65:86.
19. Mendoza TR, Wang XS, Cleeans LS, Morrisey M, Johnson BA, Wendent J, et al. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer. 1999;85:1196–9.
20. Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeans LS, et al. Validation study of the Japanese version of the brief fatigue inventory. J Pain Symptom Manag. 2003;25:106–17.
21. Kalogeris T, Bao Y, Korthuis RJ. Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. Redox Biol. 2014;2:702–14.
22. Seidman MD, Khan MI, Tang WX, Quirk WS. Influence of lecithin on mitochondrial DNA and age-related hearing loss. Otolaryngol Head Neck Surg. 2002;127:138–44.
23. Agadjanyan M, Vasilevko V, Gochikyan A, Bems P, Kesslak P, Settineri RA, et al. Nutritional supplement (NT factor®) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. J Chronic Fatigue Syndr. 2003;11:23–36.
24. Kim M, Cooper DD, Hayes SF, Spangrude GJ. Rhodamine-123 staining in hematopoietic stem cells of young mice indicates mitochondrial activation rather than dye efflux. Blood. 1998;91:4106–17.
25. Cohn JS, Kamilli A, Wat E, Chung RW, Tandy S. Dietary phospholipids and intestinal cholesterol absorption. Nutrients. 2010;116–27.
26. Cohn JS, Wat E, Kamilli A, Tandy S. Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease. Curr Opin Lipidol. 2008;19:257–62.
27. Pandey NR, Sparks DL. Phospholipids as cardiovascular therapeutics. Curr Opin Investig Drugs. 2008;9:281–5.
28. Knuman JT, Beynen AC, Katan MB. Lecithin intake and serum cholesterol. Am J Clin Nutr. 1989;49:266–8.
29. Nicolson GL, Elithorpe R. Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatigue-giving illnesses. Chronic Fatigue Syndr. 2006;13:57–68.
30. Nicolson GL, Conklin KA. Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin Exp Metastasis. 2008;25:161–9.
31. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404–11.
32. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric. 2006;9(Suppl 1):19–27.
33. Lizcano F, Guzmán G. Estrogen deficiency and the origin of obesity during menopause. Biomed Res Int. 2014;2014:757461.
34. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J. 2007;28:2028–40.
35. Rosano GM, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: the evidence. Climacteric. 2007;10(Suppl 1):19–24.
36. Leading Causes of Death in Females. Centers for Disease Control and Prevention. https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_women_heart.htm Accessed 1 Aug 2017.
37. Vitale C, Miceli M, Rosano GM. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention. Climacteric. 2007;10(Suppl 2):16–20.
38. Simons LA, Hickie JB, Ruys J. Treatment of hypercholesterolaemia with oral lecithin. Aust NZ J Med. 1977;7:262–6.
39. Wojcicki J, Pawlik A, Samochowiec L, Kaldonska M, Mysliwiec Z. Clinical evaluation of lecithin as a lipid-lowering agent. Phytother Res. 1995;9:597–9.
40. Samochowiec L, Kadlubowicka D, Rozewicka L, Kuzna W, Syzsko K. Investigations in experimental atherosclerosis.2. Effect of phosphatidylcholine (EPL) on experimental atherosclerotic changes in miniature pigs. Atherosclerosis. 1976;23:319–31.